NCT02308540View on ClinicalTrials.gov

Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

346

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

November 3, 2016

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL

SIILPCV10

10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).

BIOLOGICAL

Pneumovax 23

23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.

BIOLOGICAL

Prevenar 13

13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts

Trial Locations (1)

Unknown

Medical Research Council (MRC) Unit, The Gambia, Fajara

All Listed Sponsors

lead

PATH

OTHER

NCT02308540 - Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants | Biotech Hunter | Biotech Hunter